Results 31 to 40 of about 743,694 (262)

Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report [PDF]

, 2010
We report a 49-year-old Chinese male with locally advanced gastric adenocarcinoma achieving pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen.
Jun Wang, George W Saukel, Carlos A Garberoglio, Wichit Srikureja, Chung-Tsen Hsueh   +4 more
core   +1 more source

The prognostic and predictive power of redox rotein expression for anthracycline-based chemotherapy response in locally advanced breast cancer [PDF]

, 2012
Neoadjuvant chemotherapy has become the standard of care for locally advanced primary breast cancer. Anthracycline-based regimens have proven to be one of the most effective treatments in this setting.
A Ravid, AE Ring, AF Howie, Ahmad Al-Attar, B Chevallier, BK Arun, C Cadenas, Caroline M Woolston, CM Woolston, CM Woolston, D Mayr, D Ravi, D Shin, E Junn, HM Kuerer, I Muller, Ian O Ellis, J Huang, JA Mobley, JA Moscow, JD Pennington, JH Jeon, JO Park, L Behrend, L Gilbert, L Moureau-Zabotto, LC Alpert, Lei Zhang, LM Butler, LM Forrester, LM Mcshane, M Valko, MM Montano, Mohamed Shehata, S Toyokuni, Sarah J Storr, SH Han, SM Mense, Stephen Y Chan, Stewart G Martin, Y Nakanishi   +40 more
core   +2 more sources

The effect of tislelizumab on complete and pathological complete response in non-small cell lung cancer: a systematic review and meta-analysis

Frontiers in Oncology
BackgroundImmune checkpoint inhibitors have transformed non-small cell lung cancer (NSCLC) treatment, and while overall survival (OS) and progression-free survival (PFS) are well-established, a comprehensive meta-analysis focusing on complete response ...
Qian Feng, Xiaoxia Yan, Liping Gao, Hui Li, Baik Sarah, Russo Anna, Hongying Jiang   +6 more
doaj   +1 more source

The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery

Journal of the Egyptian National Cancer Institute, 2021
Background Management of the node-positive axilla after neoadjuvant chemotherapy is controversial. The aim of this study is to predict the group of patients who may require a less invasive approach for axillary management. One possible group are patients
Mina M. G. Youssef, Ahmed A. Metwally, Tamer M. Manie   +2 more
doaj   +1 more source

Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer [PDF]

, 2013
Background : Preoperative radiotherapy (RT) decreases local recurrence rate and improves survival in stage II and III rectal cancer patients. The combination of chemotherapy with RT has a sound radiobiological rationale, and phase II trials of combined ...
Ceelen, Wim, DE CALUWE, LAURA, Van Nieuwenhove, Yves   +2 more
core   +1 more source

Impact of remnant vital tissue after locoregional treatment and liver transplant in hepatocellular cancer patients. A multicentre cohort study [PDF]

, 2018
The role of pathological findings after locoregional treatments as predictors of hepatocellular cancer recurrence after liver transplantation has been poorly addressed.
Angelico, Mario, Angelico, Roberta, Carvalheiro, Amanda, Iesari, Samuele, Komuta, Mina, Lai, Quirino, Lerut, Jan, Manzia, Tommaso M., Montalti, Roberto, Nicolini, Daniele, Orlacchio, Antonio, Palmieri, Giampiero, Perera, M. Thamara P. R., Quaranta, Claudia, Scarpelli, Marina, Shah, Tahir, Tisone, Giuseppe, Vivarelli, Marco   +17 more
core   +1 more source

Gemcitabine, Docetaxel, Melphalan, Carboplatin as Part of Sequential Cycles of High‐Dose Chemotherapy With Autologous Hematopoietic Stem‐Cell Rescue for Multiply Relapsed/Refractory Pediatric Germ Cell Tumors

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Although most malignant germ cell tumors (GCTs) are highly curable with cisplatin‐based therapy, options for patients with multiply relapsed/refractory disease remain limited. For this population, we report the first pediatric use of gemcitabine, docetaxel, melphalan, and carboplatin (GemDMC) as part of sequential cycles of high‐dose ...
Maria Frost, Olayinka Okeleji, Amr Elgehiny, Douglas Harrison, Cynthia Herzog, Jeremy Connors, Demetrios Petropoulos, Priti Tewari, Dristhi Ragoonanan, Yago Nieto, Irtiza N. Sheikh   +10 more
wiley   +1 more source

Preoperative chemoradiation in carcinoma esophagus: Experience from a tertiary cancer center in India

Indian Journal of Medical and Paediatric Oncology, 2018
Background: Esophageal cancer is the fourth most common cause of cancer-related deaths in India. In 2012, the CROSS trial evaluated the benefit of induction therapy using weekly carboplatin-paclitaxel with 41.4 Gy radiation versus surgery alone ...
Harjot Kaur Bajwa, Rohith Singareddy, Mahendra M Reddy, Krishnam A Raju, Subramanyeshwar T Rao, Senthil J Rajappa   +5 more
doaj   +1 more source

Complete Pathological Response to Neoadjuvant Pembrolizumab in a Patient With Chemoresistant Upper Urinary Tract Urothelial Carcinoma: A Case Report

Frontiers in Oncology, 2020
Treatment options as second-line therapy for advanced ureteral carcinoma are limited, and patients experiencing recurrence after first-line cisplatin-based chemotherapy have a poor prognosis.
Daiki Ikarashi, Daiki Ikarashi, Daiki Ikarashi, Shigehisa Kitano, Kazuyuki Ishida, Tetsuya Nakatsura, Hitoshi Shimodate, Takashi Tsuyukubo, Daichi Tamura, Renpei Kato, Tamotsu Sugai, Wataru Obara   +11 more
doaj   +1 more source

A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma

Medicina, 2022
Background and Objectives: Complete pathological response after ipilimumab and nivolumab combination therapy in a patient with intermediate prognosis renal cell carcinoma is an uncommon finding.
Hana Studentova, Anezka Zemankova, Martina Spisarova, Daniela Skanderova, Zbynek Tudos, Bohuslav Melichar, Vladimir Student   +6 more
doaj   +1 more source